Management Team

John L. McManus. Mr. McManus began as a consultant to the Company in June 2005 as President. He became employed as our President and Chief Operating Officer in July 2006 and was appointed President and Chief Executive Officer in March 2007. Mr. McManus, who received his degree in business administration from the University of Southern California in 1986, is the founder and president of McManus Financial Consultants, Inc. (“MFC”), which provides strategic, financial and investor relations advice to senior managements and boards of directors of public companies, including advice on mergers and acquisitions. These companies have a combined value of over $25 billion. He has served as president of MFC since 1997. In addition, Mr. McManus previously served as Vice President, Finance and Strategic Planning to Spectrum Pharmaceuticals, Inc. where he had primary responsibility for restructuring Spectrum’s operations and finances, including the design of strategic and financial plans to enhance Spectrum’s corporate focus, and leading the successful implementation of these plans. The implementation of these plans led to an increase in Spectrum’s market value from $1 million to more than $125 million at the time of Mr. McManus’ departure.

Dr. Day is a consultant and was appointed Chief Scientific Officer of Aeolus Pharmaceuticals in September 2004. Dr. Day received his PhD in Pharmacology and Toxicology from Purdue University in 1992 and did his post doctoral training at Duke University from 1992 to 1995. He has extensive training in both pharmacology and toxicology with over 18 years of experience. Since 1994 he has helped guide the design and synthesis of metalloporphyrins and has discovered a number of their novel activities in biological systems. Dr. Day has authored over a 100 original scientific publications and served as a consultant to biotechnology companies for over 16 years. He is an active member of a number of scientific societies including the American Chemical Society, American Thoracic Society, Society for Free Radicals in Biology and Medicine, and Society of Toxicology. Dr Day is on the editorial board of Biochemical Pharmacology and was a member of the NIH Lung Injury, Repair and Remodeling Study Section from 2005 to 2009. Dr. Day has been at National Jewish Health since 1997 where he is a Vice Chair and Professor of Medicine. He is one of the scientific co-founders of Aeolus Pharmaceuticals and an inventor on a majority of the catalytic antioxidant program’s patents.

Mr. Stanley has been with the company since 2011. He has 22 years of experience in the FDA regulated pharmaceutical / biotech industry, including responsibility for global supply chain management for Spectrum Pharmaceuticals, where he saved the company $2 million per year in operating expenses. Prior to this, he held management positions at Dendreon Corp. and IDEC Pharmaceuticals. Mr. Stanley has extensive expertise in CMC, including oversight of GMP/GLP/GCP (GxP) systems. He has served as Quality/Validation lead for four different companies for multiple FDA inspections. Mr. Stanley has been involved in the development of numerous early and late-stage pharmaceutical/biotech products, as well as BLA/NDA submissions and marketed product launches.

David C. Cavalier has been the Chairman of our Board since April 30, 2004. Since 2001, he has been a founding Principal and the Chief Operating Officer of Xmark Opportunity Partners, LLC, a manager of a family of private investment funds. Prior to founding Xmark, Mr. Cavalier worked for Tiger Real Estate Partners, LLC, a $785 million private investment fund sponsored by Tiger Management Corporation. Mr. Cavalier began his career in the Investment Banking Division of Goldman, Sachs & Co. working on debt and equity offerings for public and private real estate companies. He also serves as the Chairman of the New York Advisory Board of Enterprise Community Partners, Inc., a national nonprofit and leading provider of capital and expertise for affordable housing and community development. He received a B.A. from Yale University and an M.Phil. from Oxford University.